858 Therapeutics Email Formats
Contact top employees from
858 Therapeutics
- 858 Therapeutics uses 6 formats total. Most emails use lastNameInitial-firstNameInitial: d-j@8five8tx.com. This shows up in about 81% of work addresses.
- Other common patterns:
- firstNamelastNameInitial → janed@8five8tx.com
- lastName → doe@8five8tx.com
Popular 858 Therapeutics's Email Templates
| 858 Therapeutics ’s Employees Email Address Formats | Percentage | |
|---|---|---|
Employees Email Address Formats lastNameInitial-firstNameInitial |  d-j@8five8tx.com | Percentage: 81% |
Employees Email Address Formats lastName | doe@8five8tx.com | Percentage: 11% |
Employees Email Address Formats firstNamelastNameInitial | janed@8five8tx.com | Percentage: 4% |
Employees Email Address Formats firstName_lastName | jane_doe@8five8tx.com | Percentage: 2% |
Employees Email Address Formats firstNameInitiallastNameInitial | jd@8five8tx.com | Percentage: 1% |
Employees Email Address Formats firstNamelastName | janedoe@8five8tx.com | Percentage: 1% |
Contact top employees from
858 Therapeutics
S
Sanjay Trehan
Senior Vice President, Business Development
J
Jim Veal
Chief Scientific Officer
K
Kimberly
Human Resources Director/Site Manager
J
John Holleran
Director
S
Shyama Sidique
Principal Scientist
R
Ryan Stansfield
Director
M
Milos Lazic
Senior Scientist
L
Lily Kwok
Associate Scientist
L
Lu Tian
Scientist
A
Angie Santini
Consultant
N
Nam Nguyen
Associate Director, Computational Biology
U
Umi Chong
Sr. Director of Finance and Controller
A
Amy Salyards
Senior Research Associate
Companies Similar to 858 Therapeutics
Data Privacy
GDPR COMPLIANT
SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.
CCPA COMPLIANT
SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.
